Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells

Cancer Research

Volumn 56, Issue 7, 1996, Pages 1648-1653

  Bálint, Éva ^a   Reisman, David ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BURKITT LYMPHOMA; GENES, P53; HUMANS; MUTATION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029864386     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Lane, D. p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
2. Donehower, L. A., and Bradley, A The tumor suppressor p53. Biochem. Biophys. Acta., 1155: 181-205, 1993.
3. Levine, A. J., Perry, M. E., Chang, A., Silver, A., Dittmer, D., and Welsh, D. The 1993 Walter Hubert Lecture: the role of the p53 tumor suppressor gene in tumorigenesis. Br. J. Cancer, 69: 409-416, 1994.
4. Prives, C. How loops, β sheets, and α helices help us to understand p53. Cell, 78: 543-546, 1994.
5. Kastan, M. B., Zhan, Q , El-Deiry, W. S., Carner, F., Jacks, T , Walsh, W. V., Plunkett, B. S., Vogelstein, B , and Fornance, A J , Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell, 71: 587-597, 1992.
6. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (Lond.), 352. 345-347, 1991.
7. Lowe, S. W., Schmitt, E M., Smith, S W., Osborne, B. A., and Jacks, T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993
8. Clarke, A. R , Purdie, C. A , Harrison, D. J., Morris, R. G., Bird, C C., Hooper, M L., and Wyllie, A. H Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
9. Livingstone, L. R., White, A., Sprouse, J , Livanos, E., Jacks, T , and Tlsty, T D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 Cell, 70: 923-935, 1992
10. Yin, Y., Tainsky, M A , Bischoff, F Z., Strong, L. C., and Wahl, G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992
11. Perry, M A , Piette, J , Zawadzki, J. A., Harvey, D., and Levine, A J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 90. 11623-11627, 1993.
12. El-Deiry, W S., Tokino, T , Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D , Mercer, W. E., Kinzler, K W. and Vogelstein, B WAF1, a potential mediator of p53 tumor suppression. Cell, 75 817-825, 1993.
13. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80. 293-299, 1995
14. Smith, M L , Chen, I T , Zhan, Q., Bea, I., Chen, C Y., Gilmer, T., Kastan, M B , O'Conner, P M , and Fornace, A J Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376-1378, 1994
15. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication with PCNA. Nature (Lond ), 369: 574-578, 1994.
16. 1 cyclin-dependent kinases. Cell, 75. 805-816, 1993.
17. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. Wild-type p53 binds to the TATA-binding protein and represses transcription Proc Natl. Acad. Sci. USA, 89: 12028-12032, 1992
18. Braithwaite, A W , Sturzbecher, H-W., Addison, C., Palmer, C., Rudge, K., and Jenkins, J. R Mouse p53 inhibits SV40 origin-dependent DNA replication Nature (Lond ), 329 458-460, 1987.
19. Wang, E. H , Friedman, P. N., and Prives, C. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen Cell, 57. 379-392, 1989
20. Cox, L S , Hupp, T , Midgley, C. A , Lane, D. P. A direct effect of activated human p53 on nuclear DNA replication. EMBO J , 14 2099-2105, 1995.
21. Dutta, A., Ruppert, J M., Aster, J C., and Winchester, E. Inhibition of DNA replication factor RPA by p53. Nature (Lond ), 365. 79-82, 1993
22. Cho, Y., Gorina, S., Jeffrey, P D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex, understanding tumorigenic mutations. Science (Washington DC), 265: 346-355, 1994.
23. Dittmer, D., Pati, S , Zambetti, G., Chu, S , Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53 Nat. Genet., 4: 42-46, 1993.
24. Eltyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (Lond ), 312: 646-649, 1984.
25. Parada, L F , Land, H., Weinberg, R. A., Wolf, D , and Rotter, V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (Lond.), 312. 649-651, 1984.
26. Farrell, P. J., Allan, G. J., Shanahan, F., Vousden, K. H , and Crook, T p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J., 10; 2879-2887, 1991
27. Klein, G Epstein-Barr virus strategy in normal and neoplastic B cells Cell. 77: 791-793, 1994.
28. Neri, A., Barriga, F., Inghirami, G., Knowles, D. M , Neequaye, J., Magrath, I. T., and Dalla-Favera, R. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood, 77: 1092-1095, 1991.
29. Bhatia, K. G , Gutierrez, M. I. Huppi, K., Siwarski, D., and Magrath, I T The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res., 52: 4273-4276, 1992.
30. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb E. W , Magrath, I. T , Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991
31. Wiman, K. G., Magnusson, K. P., Ramqvist, T., and Klein, G Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene, 6: 1633-1639, 1991
32. Spencer, C. A., and Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res., 56: 1-48, 1991.
33. ar-Rushdi, A., Nishikura, K., Erikson, J., Watt, R , Rovera, G., and Croce, C. M. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science (Washington DC), 222: 390-393, 1983.
34. Bhatia, K , Huppi, K., Spangler, G., Siwarski, D., Iyer, R , and Magrath, I. Point mutations in the c-myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet. 5: 56-61, 1993
35. Gupta, S., Seth, A., and Davis, R. J Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc. Natl. Acad. Sci. USA, 90: 3216-3220, 1993.
36. Roy, B., Bearnon, J., Baαlint, Eα., and Reisman, D. Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors Mol. Cell. Biol., 14: 7805-7815, 1994.
37. Finlay, C A., Hinds, P. W., Tan, T-H., Eliyahu, D., Oren, M., and Levine, A J. Activating mutation for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol , 8: 531-539, 1988.
38. Polack, A., Eick, D., Koch, E., and Bornkamm, G. W. Truncation does not abrogate transcriptional downregulation of the c-myc gene by sodium butyrate in Burkitt's lymphoma cells. EMBO J., 6: 2959-2964, 1987.
39. Felder, M. R., Watson, G., O'Malley Huff, M., and Ceci, J. D. Mechanism of induction of mouse kidney alcohol dehydrogenase by androgen. J. Biol. Chem., 263: 14531-14537, 1988.
40. Baumbach, L L., Marashi, F , Plumb, M., Stein, G., and Stein, J. Inhibition of DNA replication coordinately reduces cellular levels of core and H1 histone mRNAs: requirement for protein synthesis. Biochemistry, 23. 1618-1625, 1984.
41. Dony, C., Kessel, M., and Gruss, P. Post-transcriptional control of myc and p53 expression during differentiation of the embryonal carcinoma cell line F9. Nature (Lond.), 317: 636-639, 1985.
42. Skouv, J., Jensen, P. O., Forchhammer, J., Larsen, J. K., and Lund, L. R. Tumorpromoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth & Differ., 5: 329-340, 1994.
43. Nelson, W. G., and Kastan, M B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
44. Altus, M. S., and Nagamine, Y. Protein synthesis inhibition stabilizes urokinase-type plasminogen activator mRNA. J. Biol Chem., 266: 21190-21196, 1991.
45. Naribu, R., Menoud, P-A , and Nagimine, Y. Multiple instability-regulating sites in the 3′ untranslated region of the urokinase-type plasminogen activator mRNA. Mol. Cell. Biol., 14: 4920-4928, 1994.
46. Osley, M. A. The regulation of histone synthesis in the cell cycle. Annu. Rev. Biochem., 60: 827-861, 1991.
47. Cory, J. G., Cory, A. H., Long, S. D., Carter, G L., and Johnson, C. E. Altered steady-state levels of the messenger RNAs for c-myc and p53 in L1210 cell lines resistant to deoxyadenosine Cancer Res., 52: 2000-2003, 1992